Literature DB >> 14730327

Neutral endopeptidase and angiotensin I converting enzyme insertion/deletion gene polymorphism in humans.

J E Jalil1, M P Ocaranza, C Oliveri, S Córdova, I Godoy, G Chamorro, S Braun, C Fardella, J-B Michel, S Lavandero.   

Abstract

Neutral endopeptidase (NEP) hydrolyses angiotensins (Ang) I and II and generates angiotensin-(1-7) [Ang-(1-7)]. In humans, the insertion/deletion (I/D) angiotensin-I converting enzyme (ACE) gene polymorphism determined plasma ACE levels by 40%. In rats, a similar polymorphism determines ACE levels which are inversely associated to NEP activity. The objective of this study is to evaluate the relationship between ACE expression and plasma NEP activity in normotensive subjects and in hypertensive patients. In total, 58 consecutive patients with hypertension, evaluated in our Hypertension Clinic, were compared according to their ACE I/D genotypes with 54 control subjects in terms of both plasma ACE activity and NEP activities. Plasma ACE activity was elevated 51 and 70% in both DD ACE groups (normotensives and hypertensives) compared with their respective ID and II ACE groups (P<0.001). A significant effect of the ACE polymorphism and of the hypertensive status on ACE activity was observed (P<0.001). In normotensive DD ACE subjects, NEP activity was 0.30+/-0.02 U/ml, whereas in the normotensive II ACE and in the normotensive ID ACE subjects NEP activity was increased 65 and 48%, respectively (P<0.001). In the hypertensive DD ACE patients, NEP activity was 0.47+/-0.03 U/mg. An effect of the I/D ACE genotypes on NEP activity (P<0.04) and an interaction effect between the I/D ACE genotype and the hypertensive status were also observed (P<0.001). These results are consistent with a normal and inverse relationship between the ACE polymorphism and NEP activity in normotensive humans (as is also observed in rats). This normal relationship is not observed in hypertensive patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14730327     DOI: 10.1038/sj.jhh.1001646

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  4 in total

1.  Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease.

Authors:  Matthew L Hemming; Dennis J Selkoe; Wesley Farris
Journal:  Neurobiol Dis       Date:  2007-01-25       Impact factor: 5.996

2.  Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes.

Authors:  Scott Miners; Emma Ashby; Shabnam Baig; Rachel Harrison; Hannah Tayler; Elizabeth Speedy; Jonathan A Prince; Seth Love; Patrick G Kehoe
Journal:  Am J Transl Res       Date:  2009-01-18       Impact factor: 4.060

3.  Neprilysin, obesity and the metabolic syndrome.

Authors:  K F Standeven; K Hess; A M Carter; G I Rice; P A Cordell; A J Balmforth; B Lu; D J Scott; A J Turner; N M Hooper; P J Grant
Journal:  Int J Obes (Lond)       Date:  2010-11-02       Impact factor: 5.095

Review 4.  Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function.

Authors:  Carlos M Ferrario; Aaron J Trask; Jewell A Jessup
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-07-29       Impact factor: 4.733

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.